Amendments to the Claims

Please cancel Claims 2, 6 and 13.

Please amend Claims 1, 3-5, 7-8, 11-12, and 14-15.

Please add new Claims 16-25.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of treating TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody competitively inhibits binding of ~~TNF~~ human TNFα to anti-TNFα chimeric monoclonal antibody cA2.

2. (Canceled)

3. (Currently Amended) A method of treating TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of ~~chimeric anti-TNF~~ anti-TNFα chimeric monoclonal antibody cA2.

4. (Currently Amended) A method for treating TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human at least one anti-TNFα chimeric monoclonal antibody cA2, or an antigen-binding ~~a TNF binding~~ fragment thereof.

5. (Currently Amended) A method of treating TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric

antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of ~~TNF~~ human TNFα to anti-TNFα chimeric monoclonal antibody cA2.

6. (Canceled)

7. (Currently Amended) A method of treating TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

8. (Currently Amended) A method of treating TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.

10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.

11. (Currently Amended) A method of treating ~~inflammation associated with~~ TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.

12. (Currently Amended) A method of treating inflammation associated with TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody competitively inhibits binding of ~~TNF~~ human TNFα to anti-TNFα chimeric monoclonal antibody cA2.

13. (Canceled)

14. (Currently Amended) A method of treating inflammation associated with TNFα-mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of ~~chimeric anti-TNF~~ anti-TNFα chimeric monoclonal antibody cA2.

15. (Currently Amended) A method of treating inflammation associated with TNF-α mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.

16. (New) The method of Claim 1 wherein said chimeric anti-TNFα antibody binds to a neutralizing epitope of human TNFα.

17. (New) A method of treating TNFα-mediated hepatitis in a human comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα antibody, wherein said anti-TNFα antibody competitively inhibits binding of human TNFα to anti-TNFα chimeric monoclonal antibody cA2.

18. (New) The method of Claim 1 wherein said anti-TNFα antibody binds with high affinity to a neutralizing epitope of human TNFα.

19. (New) The method of Claim 1 wherein said anti-TNFα antibody binds to a neutralizing epitope of human TNFα *in vivo* with an affinity of at least 1×10^8 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.

20. (New) The method of Claim 1 wherein said anti-TNFα antibody is administered to the human by means of parenteral administration.

21. (New) The method of Claim 1 wherein said anti-TNFα antibody is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.

22. (New) The method of Claim 1 wherein said anti-TNFα antibody is administered to the human orally.

23. (New) The method of Claim 1 wherein said TNFα-inhibiting amount of the anti-TNFα antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.

24. (New) The method of Claim 23 wherein said single or divided dose is selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.

25. (New) The method of Claim 1 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: radiotherapeutics, cytotoxic drugs, monoclonal antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.